论文信息 - CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. - 字舞流文

CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.

E. Petricoin | D. Zelterman | C. Hatzis | M. Pierobon | M. Mita | W. Sikov | M. Abu-Khalaf | N. Denduluri | Bryant Dunetz | K. A. Hodge | Frances Valdes | R. Murphy | K. Awerkamp